
EY Entrepreneur of the year-2013

FROST & SULLIVAN Best Practices-2013


Business today/YES bank Excellence Awards-2013

Eris Lifesciences Limited

Date: 20th April 2026

To **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	**To** **National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	**Symbol: ERIS**

SUB: INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED, CROATIA

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that HALMED (Agency for Medicinal Products and Medical Devices of Croatia) had inspected Swiss Parenterals Ltd.'s Unit 1 and 2 situated in Ahmedabad, Gujarat from March 9th to 13th 2026. We are now in receipt of the list of non-compliance observations from the agency. We will respond to the agency within the stipulated timelines and take the necessary actions to reinstate the requisite approvals for both facilities.

The Company is committed to maintaining the highest quality manufacturing standards at its facilities. We will keep the stock exchanges informed if there is any further information relating to the above. The details in the prescribed format as required under Regulation 30 of the SEBI Listing Regulations are enclosed as Annexure.

Thanking you.

Yours faithfully,

Eris Lifesciences Limited

Milind Talegaonkar

Digitally signed by Milind Talegaonkar
Date: 2026.04.20 20:19:58 +05'30'

Milind Talegaonkar
Company Secretary and Compliance Officer

Encl: a/a

ANNEXURE

Sr No	Particulars	Details
1	Name of Authority	HALMED - Agency for Medicinal Products and Medical Devices of Croatia
2	Inspection date/s	March 9th to 13th 2026 (both days included)
3	Present status	We have received the list of non-compliance observations from the agency in Unit-1 (general liquid and dry powder injectables) and Unit-2 (betalactam dry powder injectables)
4	Nature of observations	All observations are procedural in nature, requiring improvement to achieve compliance with the principles and guidelines of GMP under the Directive (EU) 2017/1572
5	Next steps for us	• Execute remediation actions and submit the CAPAs • Request the agency to conduct a follow-on inspection
6	Business impact	• Minimal impact on existing business • Delay in the commercialization of EU-CDMO product pipeline